RankAlpha logo
Back to Rankings

RCUS

Arcus BiosciencesD
NYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
The ARC-20 update showed encouraging first-, second- and late-line casdatifan signals, including 14.5-month median PFS for the second-line combination and 35-month median overall survival in pooled late-line monotherapy cohorts. Successful randomized validation could materially expand the RCC opportunity.
Posture
Defensive
Lead driver
Sentiment
What changed
Next scheduled catalyst: earnings 2026-11-04 · AMC.
What can break
PEAK-20 initiation and PEAK-1 enrollment or results could be delayed, and casdatifan has not received regulatory approval. [#PR-2026-10-20]
Momentum
9
Value
41
Sentiment
51
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $17.00 · Bull $28.00 · Bear $10.00Analysis 2026-10-22; returns require an exact persisted reference.
Earnings
2026-11-04 · AMC
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-30 • Vendor: Data Vendor v1
Scores
As of 2026-10-30 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-22 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-30

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-30. Definitions

Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $41.00
Why
Momentum9 · Δ7d -12.8
Value41 · Δ7d +0.0
Sentiment51 · Δ7d +9.4
So what
Weak posture (Net Neutral). Prioritize risk control and patience.

Confirming evidence

  • • Next scheduled catalyst: earnings 2026-11-04 · AMC.
  • • Sentiment remains the lead driver in the composite, 7D delta +9.4.

Contradictions & invalidation

  • • PEAK-20 initiation and PEAK-1 enrollment or results could be delayed, and casdatifan has not received regulatory approval. [#PR-2026-10-20]
  • • The October 20 efficacy comparisons use third-party historical benchmarks, not randomized head-to-head trials; Phase 3 results may differ. [#PR-2026-10-20]
  • • Small, nonrandomized cohorts and historical comparators may overstate the eventual Phase 3 benefit.

Catalyst clock

2026-11-04 · AMC

Public offering puts dilution and pricing in focus

Lead driver: Sentiment · See AI snapshot
Momentum
9
8% active weight
Current posture
7d trendSoftening
Δ7d
-12.8
Δ21d
-12.8
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.2
Sentiment
51
45% active weight
Current posture
7d trendImproving
Δ7d
+9.4
Δ21d
-26.0
Why this grade

Composite grade D. Momentum 8.9 / Value 40.6 / Sentiment 50.7

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-22. Scenario method

B+
Bull case
20%
Probability
Target price
$28.00
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
Most likely
B
Base case
45%
Probability
Target price
$17.00
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$10.00
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-30
Market Cap
$2.58B
Beta
0.85
Shares Out
127.33M
P/E (TTM) · Derived
-6.2
P/S (TTM)
11.14
P/FCF (TTM) · Derived
-5.09
Rev YoY
-74.4%
EPS YoY
-10.3%
Gross Margin
+92.3%
Op Margin
-415.4%
Net Debt
-$783M
Current Ratio
3.82
As of 2026-10-30 • Updated nightlySource: Internal modelMethods & Data